Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Front Genet. 2019 Oct 18:10:1008. doi: 10.3389/fgene.2019.01008. eCollection 2019.

Abstract

Worldwide, especially in China, lung cancer accounts to a major cause of mortality related to cancer. Treatment decisions mainly depend on oncogenic driver mutations, which offer novel therapeutic targets for anticancer therapy. However, studies of genomic profiling of driver gene mutations in mainland China are rare. Hence, this is an extensive study of these mutations in Non-small-cell lung cancer (NSCLC) Chinese patients. Comparison of driver gene mutations of lung adenocarcinoma with other races showed that the mutational frequencies were similar within the different East Asian populations, while there were differences between East Asian and non-Asian populations. Further, four promising candidates for druggable mutations of epidermal growth factor receptor (EGFR) were revealed that open up avenues to develop and design personal therapeutic approaches for patients harboring mutations. These results will help to develop personalized therapy targeting NSCLC.

Keywords: EGFR; driver mutations; epidemiology; lung cancer; personalized medicine.